Overview

A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants

Status:
Completed
Trial end date:
2018-02-06
Target enrollment:
Participant gender:
Summary
This study compares LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs are given by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels in comparison with insulin lispro. The study will last about 7 to 12 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc